BIO-TECHNE Corp vs Yum China Holdings Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Yum China Holdings Inc trades at $43.23 (market cap $13.73B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Yum China Holdings Inc for 77 Days on average.
| TECH | YUMC | |
|---|---|---|
Market Cap | $11.37B | $13.73B |
Volume | 3,153,511 | 1,639,796 |
Sector | Health | Consumer Cyclical |
52-Week High | $72.61 | $57.95 |
52-Week Low | $43.31 | $39.98 |
Typical Hold Time | 63 Days | 77 Days |
Enterprise Value | $11.40B | $14.64B |
Dividend Yield | 0.44% | 2.85% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
YUMC trades at $41.78, up 2.86% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth from $11.8B in 2025 to projected $12.4B in 2026, with net profit margins around 7.8%. Recent developments include Pizza Hut Burger Bar expansion to 300 locations and full ownership acquisition of Pizza Hut China brand, signaling strategic growth initiatives.
YUMC presents a value opportunity with attractive valuation ratios (P/E 14.89, P/S 1.17) and strong analyst support (74% buy ratings). However, technical weakness and China economic exposure pose near-term risks. The 25.6% analyst upside potential suggests significant undervaluation if execution continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →